No Data
No Data
Stocks in Hong Kong are rising sharply. Peijia Medical-B (09996) is up more than 6%. Its revenue increased by the most 37.8% in the first half of the year. JenaValve has been wholly acquired by Edwards Lifesciences.
Peijia Medical -B (09996) rose by over 6%. As of press time, it rose 6.18% to HKD 2.75, with a turnover of HKD 10.8212 million.
Peijia Medical -B (09996.HK) plans to hold a board of directors meeting on August 23 to approve its interim performance.
Peijia Medical - B (09996.HK) announced that the board of directors will hold a meeting on Friday, August 23, 2024 to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending on June 30, 2024, including the proposal to pay a mid-term dividend (if any).
PEIJIA-B: DATE OF BOARD MEETING
HK stocks fluctuate | Peijia Medical-B (09996) is now down more than 8%. In the first half of the year, the income growth was the highest at 37.8%. Institutions said that the growth was slightly lower than expected.
Peijia Medical-B (09996) is now down more than 8%. As of press time, it has fallen by 6.2% to HKD 2.42, with a turnover of HKD 6.866 million.
JenaValve, a partner of Perk Jia Medical, has been fully acquired by Edwards Lifesciences, marking a new chapter in the treatment of aortic valve regurgitation through catheterization.
Suzhou, July 26, 2024 / PRNewswire / -- On July 24, 2024, Peijia Medical (9996.HK) partner JenaValve Technology, Inc. (hereinafter referred to as JenaValve) announced an agreement with the US medical equipment giant Edwards Lifesciences (NYSE: EW, hereinafter referred to as "Edwards") for Edwards Lifesciences to acquire JenaValve wholly. After the transaction, Peijia Medical will continue to exclusively hold the JenaValve Trilogy THV system in the Greater China region.
Peijia Medical-B (09996.HK): Edwards Lifesciences plans to acquire JenaValve through a merger.
On July 26th, Guolong News reported that Peijia Medical-B (09996.HK) announced that its wholly-owned subsidiary, Marvel Finder Limited, holds about 1.91% (calculated on a fully diluted and conversion basis) of JenaValve's minority equity, which is recorded in the company's comprehensive financial statements as a financial asset measured at fair value. JenaValve has notified the company that on July 23, 2024 (US time), Edwards Lifesciences (through its wholly-owned subsidiary) agreed to acquire the shares.
No Data